Scott L. Burrows - Sep 3, 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Sep 3, 2024
Transactions value $
-$522,074
Form type
4
Date filed
9/5/2024, 04:04 PM
Previous filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRE Common Stock Sale -$522K -18.5K -13.73% $28.17 116K Sep 3, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,739 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person.
F2 The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $27.72 to $28.18, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 101,214 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in three equal installments on each of September 1, 2025, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.